Biopharmaceuticals Market Forecasts to 2030 – Global Analysis By Product Type (Monoclonal Antibodies, Interferon, Insulin, Growth and Coagulation Factor, Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Synthetic Immunomodula

Biopharmaceuticals Market Forecasts to 2030 – Global Analysis By Product Type (Monoclonal Antibodies, Interferon, Insulin, Growth and Coagulation Factor, Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Synthetic Immunomodulators, Recombinant Hormones, Recombinant Enzymes, Cell and Gene Therapies, Synthetic Immunomodulators and Other Product Types), Application and By Geography


According to Stratistics MRC, the Global Biopharmaceuticals Market is accounted for $1047.45 million in 2023 and is expected to reach $2686.05 million by 2030 growing at a CAGR of 14.4% during the forecast period. Biopharmaceuticals, also referred to as biologic drugs or biologics, are pharmaceuticals made from living things like cells, organisms, or proteins. These medications are produced using biotechnology techniques and are essential to contemporary healthcare. Moreover, biopharmaceuticals have made it possible to develop personalized medicine strategies. These medications have the potential to target particular molecular aspects of a patient's illness, enabling the development of personalized treatment plans based on the patient's particular genetic profile or disease subtype.

According to the International Agency for Research on Cancer, in the year 2020, around 19.3 million new cases of cancer were diagnosed and around 10 million cancer deaths were recorded. The cancer cases are estimated to grow by 47% from 2020 to 2040.

Market Dynamics

Driver

Expanding scientific advances

Biopharmaceutical R&D is being transformed by ongoing scientific advances in structural biology, gene editing, and high-throughput screening methods. Drug design is aided by the understanding of bimolecular structures provided by cryo-electron microscopy and cutting-edge imaging technologies. Massive datasets are analyzed using artificial intelligence and machine learning to make predictions about drug discovery. Additionally, gene therapies and gene-edited cell therapies have been made possible by advances in synthetic biology, such as CRISPR-Cas9, expanding the range of biopharmaceuticals.

Restraint

Excess development costs

Financial investments in research, preclinical studies, and challenging clinical trials are significant in the development of biopharmaceuticals. In addition to these basic costs, biopharmaceutical businesses also have to spend money on specialized infrastructure, such as state-of-the-art lab tools and specialized manufacturing facilities, all of which drive up development costs. Furthermore, the lengthy and resource-intensive nature of biopharmaceutical development, where costs frequently exceed billions of dollars for a single drug candidate, further exacerbates financial difficulties.

Opportunity

Increasing clinical trials and personalized medicine

Precision medicine, which tailors treatments to a person's genetic profile and particular disease characteristics, is being made possible by developments in genomics and molecular diagnostics. With this strategy, treatment effectiveness is improved, side effects are minimized, and patient outcomes are optimized. Moreover, oncology is a field where personalized medicine holds particular promise because biomarker-driven therapies are increasing survival and response rates.

Threat

Challenges to intellectual property (IP)

A complex web of patents, trade secrets, and patent thickets must be negotiated by businesses due to the global nature of the biopharmaceutical market, which presents additional IP challenges. Additionally, the emergence of biosimilars brings with it new legal complexities, such as patent disputes and patent thicket strategies, where multiple patents are used to cover a single product and provide for extended market exclusivity.

Covid-19 Impact

The COVID-19 pandemic affected the biopharmaceutical industry significantly and in a variety of ways. In addition to delaying clinical trials, disrupting global supply chains, and refocusing resources on pandemic-related activities, the urgent need for vaccines and treatments accelerated research and development efforts. Moreover, the pandemic highlighted the significance of vaccine development, antiviral therapies, and biopharmaceutical innovation, leading to increased investments in these fields. It also exposed weaknesses in supply chains, forcing businesses to reconsider their distribution and manufacturing plans.

The Vaccines segment is expected to be the largest during the forecast period

The vaccines segment typically holds the largest share of the market. A wide range of infectious diseases are prevented by vaccines, which are essential to public health. They have become more well-known for both current threats like COVID-19 and emerging ones like influenza and hepatitis. The global demand for vaccines has increased dramatically as a result of the COVID-19 pandemic in particular. However, the vaccine market is still essential to the expansion of the biopharmaceutical industry and efforts to improve public health due to ongoing research and development activities, including the creation of new vaccine platforms like mRNA vaccines.

The Oncology segment is expected to have the highest CAGR during the forecast period

The biopharmaceutical market's highest CAGR is anticipated in the oncology segment. This is mainly because of a number of things, such as the rising incidence of cancer globally, developments in targeted and immunotherapeutic therapies, and ongoing work on precision medicine methods. Moreover, the oncology market has experienced significant growth as a result of the creation of novel biopharmaceuticals for various cancer types as well as the potential for combination therapies and biomarker-driven treatments.

Region with largest share

The global biopharmaceutical market typically holds the largest share in the North American region, in particular the United States. A strong pharmaceutical industry, significant R&D expenditures, a developed healthcare system, a sizable patient base, and a supportive regulatory environment for the development and commercialization of biopharmaceuticals were all cited as contributing factors to this dominance. Additionally, its sizeable market share was influenced by the fact that North America is home to a large number of biopharmaceutical businesses, academic research centers, and biotechnology hubs.

Region with highest CAGR

The biopharmaceutical market was growing at the highest CAGR in the Asia-Pacific region. A rising middle-class population, rising healthcare costs, growing pharmaceutical manufacturing capacity, and rising demand for cutting-edge treatments are just a few of the reasons for this industry's rapid growth. Due to their investments in R&D, clinical trials, and the production of biologic drugs and vaccines, nations like China and India in particular were emerging as major players in the biopharmaceutical industry. Moreover, the region's rapid growth was also aided by supportive government policies and partnerships with major pharmaceutical corporations.

Key players in the market

Some of the key players in Biopharmaceuticals market include Merck & Co., Inc. , Novartis AG, Abbott Laboratories., Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca PLC, Bristol-Myers Squibb Company, Biogen Inc. , AbbVie Inc., Pfizer Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Sanofi, Bayer AG, Allergan plc , Johnson & Johnson and Amgen Inc.

Key Developments

In October 2023, Sanofi has reached an agreement to develop and commercialize an experimental vaccine candidate for extra intestinal pathogenic E. coli developed by Janssen Pharmaceuticals. Under the terms of the deal, Sanofi will pay the Johnson & Johnson unit $175m upfront, followed by development and commercial milestones. Both parties will co-fund current and future research and development costs. Extra intestinal pathogenic E. coli is a common gram-negative bacteria pathogen in humans and a leading cause of sepsis, particularly in older adults.

In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company’s Library of Libraries, a collection of synthetic antibody libraries that harnesses innovative structural and develops ability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery. It has the potential to increase the probability of success of antibody discovery programs across indications and focus areas.

In September 2023, Abbott signs definitive agreement to acquire Bigfoot Biomedical. Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

Product Types Covered
• Monoclonal Antibodies
• Interferon
• Insulin
• Growth and Coagulation Factor
• Vaccines
• Recombinant Growth Factors
• Purified Proteins
• Recombinant Proteins
• Synthetic Immunomodulators
• Recombinant Hormones
• Recombinant Enzymes
• Cell and Gene Therapies
• Synthetic Immunomodulators
• Other Product Types

Applications Covered
• Oncology
• Blood disorder
• Metabolic disease
• Infectious disease
• Cardiovascular disease
• Neurological disease
• Immunology
• Autoimmune Disorders
• Hormonal Disorders
• Other Applications

Regions Covered
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Biopharmaceuticals Market, By Product Type
5.1 Introduction
5.2 Monoclonal Antibodies
5.2.1 Anti-cancer Monoclonal Antibodies
5.2.2 Anti-inflammatory Monoclonal Antibodies
5.3 Interferon
5.4 Insulin
5.5 Growth and Coagulation Factor
5.6 Vaccines
5.6.1 Recombinant Vaccines
5.6.1.1 Cancer Vaccine
5.6.1.2 Malaria Vaccine
5.6.1.3 Ebola Vaccine
5.6.1.4 Hepatitis-B Vaccine
5.6.1.5 Tetanus Vaccine
5.6.1.6 Diphtheria Vaccine
5.6.1.7 Cholera Vaccine
5.6.2 Conventional Vaccines
5.6.2.1 Polio Vaccine
5.6.2.2 Pox Vaccine
5.7 Recombinant Growth Factors
5.7.1 Erythropoietin
5.7.2 Granulocyte Colony Stimulating Factor
5.8 Purified Proteins
5.8.1 Leukemia Inhibitory Factor (LIF)
5.8.2 P53 Protein
5.8.3 P38 Protein
5.9 Recombinant Proteins
5.9.1 Serum Albumin
5.9.2 Amyloid Protein
5.9.3 Defensin
5.9.4 Transferrin
5.10 Synthetic Immunomodulators
5.11 Recombinant Hormones
5.11.1 Recombinant Human Growth Hormones
5.11.2 Recombinant Insulin
5.12 Recombinant Enzymes
5.12.1 Enterokinase
5.12.2 Cyclase
5.12.3 Caspase
5.12.4 Cathepsin
5.13 Cell and Gene Therapies
5.13.1 Allogenic Products
5.13.2 Autologous Products
5.13.3 Acellular Products
5.14 Synthetic Immunomodulators
5.14.1 Cytokines
5.14.2 Interferons
5.14.3 Interleukins
5.15 Other Product Types
6 Global Biopharmaceuticals Market, By Application
6.1 Introduction
6.2 Oncology
6.3 Blood disorder
6.4 Metabolic disease
6.5 Infectious disease
6.6 Cardiovascular disease
6.7 Neurological disease
6.8 Immunology
6.9 Autoimmune Disorders
6.10 Hormonal Disorders
6.11 Other Applications
7 Global Biopharmaceuticals Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 US
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 UK
7.3.3 Italy
7.3.4 France
7.3.5 Spain
7.3.6 Rest of Europe
7.4 Asia Pacific
7.4.1 Japan
7.4.2 China
7.4.3 India
7.4.4 Australia
7.4.5 New Zealand
7.4.6 South Korea
7.4.7 Rest of Asia Pacific
7.5 South America
7.5.1 Argentina
7.5.2 Brazil
7.5.3 Chile
7.5.4 Rest of South America
7.6 Middle East & Africa
7.6.1 Saudi Arabia
7.6.2 UAE
7.6.3 Qatar
7.6.4 South Africa
7.6.5 Rest of Middle East & Africa
8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiling
9.1 Merck & Co., Inc.
9.2 Novartis AG
9.3 Abbott Laboratories.
9.4 Novo Nordisk A/S
9.5 Eli Lilly and Company
9.6 AstraZeneca PLC
9.7 Bristol-Myers Squibb Company
9.8 Biogen Inc.
9.9 AbbVie Inc.
9.10 Pfizer Inc.
9.11 Bausch Health Companies Inc.
9.12 F. Hoffmann-La Roche AG
9.13 Sanofi
9.14 Bayer AG
9.15 Allergan plc
9.16 Johnson & Johnson
9.17 Amgen Inc.
List of Tables
Table 1 Global Biopharmaceuticals Market Outlook, By Region (2021-2030) ($MN)
Table 2 Global Biopharmaceuticals Market Outlook, By Product Type (2021-2030) ($MN)
Table 3 Global Biopharmaceuticals Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
Table 4 Global Biopharmaceuticals Market Outlook, By Anti-cancer Monoclonal Antibodies (2021-2030) ($MN)
Table 5 Global Biopharmaceuticals Market Outlook, By Anti-inflammatory Monoclonal Antibodies (2021-2030) ($MN)
Table 6 Global Biopharmaceuticals Market Outlook, By Interferon (2021-2030) ($MN)
Table 7 Global Biopharmaceuticals Market Outlook, By Insulin (2021-2030) ($MN)
Table 8 Global Biopharmaceuticals Market Outlook, By Growth and Coagulation Factor (2021-2030) ($MN)
Table 9 Global Biopharmaceuticals Market Outlook, By Vaccines (2021-2030) ($MN)
Table 10 Global Biopharmaceuticals Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
Table 11 Global Biopharmaceuticals Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
Table 12 Global Biopharmaceuticals Market Outlook, By Recombinant Growth Factors (2021-2030) ($MN)
Table 13 Global Biopharmaceuticals Market Outlook, By Erythropoietin (2021-2030) ($MN)
Table 14 Global Biopharmaceuticals Market Outlook, By Granulocyte Colony Stimulating Factor (2021-2030) ($MN)
Table 15 Global Biopharmaceuticals Market Outlook, By Purified Proteins (2021-2030) ($MN)
Table 16 Global Biopharmaceuticals Market Outlook, By Leukemia Inhibitory Factor (LIF) (2021-2030) ($MN)
Table 17 Global Biopharmaceuticals Market Outlook, By P53 Protein (2021-2030) ($MN)
Table 18 Global Biopharmaceuticals Market Outlook, By P38 Protein (2021-2030) ($MN)
Table 19 Global Biopharmaceuticals Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
Table 20 Global Biopharmaceuticals Market Outlook, By Serum Albumin (2021-2030) ($MN)
Table 21 Global Biopharmaceuticals Market Outlook, By Amyloid Protein (2021-2030) ($MN)
Table 22 Global Biopharmaceuticals Market Outlook, By Defensin (2021-2030) ($MN)
Table 23 Global Biopharmaceuticals Market Outlook, By Transferrin (2021-2030) ($MN)
Table 24 Global Biopharmaceuticals Market Outlook, By Synthetic Immunomodulators (2021-2030) ($MN)
Table 25 Global Biopharmaceuticals Market Outlook, By Recombinant Hormones (2021-2030) ($MN)
Table 26 Global Biopharmaceuticals Market Outlook, By Recombinant Human Growth Hormones (2021-2030) ($MN)
Table 27 Global Biopharmaceuticals Market Outlook, By Recombinant Insulin (2021-2030) ($MN)
Table 28 Global Biopharmaceuticals Market Outlook, By Recombinant Enzymes (2021-2030) ($MN)
Table 29 Global Biopharmaceuticals Market Outlook, By Enterokinase (2021-2030) ($MN)
Table 30 Global Biopharmaceuticals Market Outlook, By Cyclase (2021-2030) ($MN)
Table 31 Global Biopharmaceuticals Market Outlook, By Caspase (2021-2030) ($MN)
Table 32 Global Biopharmaceuticals Market Outlook, By Cathepsin (2021-2030) ($MN)
Table 33 Global Biopharmaceuticals Market Outlook, By Cell and Gene Therapies (2021-2030) ($MN)
Table 34 Global Biopharmaceuticals Market Outlook, By Allogenic Products (2021-2030) ($MN)
Table 35 Global Biopharmaceuticals Market Outlook, By Autologous Products (2021-2030) ($MN)
Table 36 Global Biopharmaceuticals Market Outlook, By Acellular Products (2021-2030) ($MN)
Table 37 Global Biopharmaceuticals Market Outlook, By Synthetic Immunomodulators (2021-2030) ($MN)
Table 38 Global Biopharmaceuticals Market Outlook, By Cytokines (2021-2030) ($MN)
Table 39 Global Biopharmaceuticals Market Outlook, By Interferons (2021-2030) ($MN)
Table 40 Global Biopharmaceuticals Market Outlook, By Interleukins (2021-2030) ($MN)
Table 41 Global Biopharmaceuticals Market Outlook, By Other Product Types (2021-2030) ($MN)
Table 42 Global Biopharmaceuticals Market Outlook, By Application (2021-2030) ($MN)
Table 43 Global Biopharmaceuticals Market Outlook, By Oncology (2021-2030) ($MN)
Table 44 Global Biopharmaceuticals Market Outlook, By Blood disorder (2021-2030) ($MN)
Table 45 Global Biopharmaceuticals Market Outlook, By Metabolic disease (2021-2030) ($MN)
Table 46 Global Biopharmaceuticals Market Outlook, By Infectious disease (2021-2030) ($MN)
Table 47 Global Biopharmaceuticals Market Outlook, By Cardiovascular disease (2021-2030) ($MN)
Table 48 Global Biopharmaceuticals Market Outlook, By Neurological disease (2021-2030) ($MN)
Table 49 Global Biopharmaceuticals Market Outlook, By Immunology (2021-2030) ($MN)
Table 50 Global Biopharmaceuticals Market Outlook, By Autoimmune Disorders (2021-2030) ($MN)
Table 51 Global Biopharmaceuticals Market Outlook, By Hormonal Disorders (2021-2030) ($MN)
Table 52 Global Biopharmaceuticals Market Outlook, By Other Applications (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings